4OGG
| |
4OGF
| |
2KLO
| Structure of the Cdt1 C-terminal domain | Descriptor: | DNA replication factor Cdt1 | Authors: | Khayrutdinov, B.I, Bae, W.J, Yun, Y.M, Tsuyama, T, Kim, J.J, Hwang, E, Ryu, K.-S, Cheong, H.-K, Cheong, C, Karplus, P.A, Guntert, P, Tada, S, Jeon, Y.H, Cho, Y. | Deposit date: | 2009-07-06 | Release date: | 2009-10-13 | Last modified: | 2024-05-29 | Method: | SOLUTION NMR | Cite: | Structure of the Cdt1 C-terminal domain: Conservation of the winged helix fold in replication licensing factors Protein Sci., 18, 2009
|
|
2LJP
| Backbone 1H, 13C, and 15N Chemical Shift Assignments for E.coli Ribonuclease P protein | Descriptor: | Ribonuclease P protein component | Authors: | Shin, J, Kim, K, Ryu, K, Han, K, Lee, Y, Choi, B. | Deposit date: | 2011-09-21 | Release date: | 2011-12-07 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Structural analysis of Escherichia coli C5 protein To be Published
|
|
6K2K
| Solution structure of MUL1-RING domain | Descriptor: | Mitochondrial ubiquitin ligase activator of NFKB 1, ZINC ION | Authors: | Lee, M.S, Lee, M.K, Ryu, K.S, Chi, S.W. | Deposit date: | 2019-05-14 | Release date: | 2019-07-10 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Solution structure of MUL1-RING domain and its interaction with p53 transactivation domain. Biochem.Biophys.Res.Commun., 516, 2019
|
|
3IMN
| |
3INA
| Crystal structure of heparin lyase I H151A mutant complexed with a dodecasaccharide heparin | Descriptor: | 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose-(1-4)-2-O-sulfo-alpha-L-idopyranuronic acid-(1-4)-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose-(1-4)-2-O-sulfo-alpha-L-idopyranuronic acid-(1-4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose-(1-4)-2-O-sulfo-alpha-L-idopyranuronic acid-(1-4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose-(1-4)-2-O-sulfo-alpha-L-idopyranuronic acid, CALCIUM ION, Heparin lyase I | Authors: | Han, Y.H, Ryu, K.S, Kim, H.Y, Jeon, Y.H. | Deposit date: | 2009-08-12 | Release date: | 2009-09-29 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structural snapshots of heparin depolymerization by heparin lyase I J.Biol.Chem., 284, 2009
|
|
3IN9
| Crystal structure of heparin lyase I complexed with disaccharide heparin | Descriptor: | 4-deoxy-2-O-sulfo-alpha-L-threo-hex-4-enopyranuronic acid-(1-4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose, CALCIUM ION, Heparin lyase I | Authors: | Han, Y.H, Ryu, K.S, Kim, H.Y, Jeon, Y.H. | Deposit date: | 2009-08-12 | Release date: | 2009-09-29 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structural snapshots of heparin depolymerization by heparin lyase I J.Biol.Chem., 284, 2009
|
|
2LSI
| |
2MH9
| |
7ER7
| Crystal structure of hyman Biliverdin IX-beta reductase B with Tamibarotene (A80) | Descriptor: | 4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl]benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERB
| Crystal structure of human Biliverdin IX-beta reductase B with Ataluren (PTC) | Descriptor: | 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ER8
| Crystal structure of human Biliverdin IX-beta reductase B with Sulfasalazine (SAS) | Descriptor: | 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ER9
| Crystal structure of human Biliverdin IX-beta reductase B with Febuxostat (TEI) | Descriptor: | 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERA
| Crystal structure of human Biliverdin IX-beta reductase B with Olsalazine Sodium (OSS) | Descriptor: | 5-[(E)-(3-carboxy-4-oxidanyl-phenyl)diazenyl]-2-oxidanyl-benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERE
| Crystal structure of human Biliverdin IX-beta reductase B with Pyrantel Pamoate (PPA) | Descriptor: | 4-[(3-carboxy-2-oxidanyl-naphthalen-1-yl)methyl]-3-oxidanyl-naphthalene-2-carboxylic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERC
| Crystal structure of human Biliverdin IX-beta reductase B with Deferasirox (ICL) | Descriptor: | 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ER6
| Crystal structure of human Biliverdin IX-beta reductase B | Descriptor: | Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, SULFATE ION | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERD
| Crystal structure of human Biliverdin IX-beta reductase B with Flunixin Meglumin (FMG) | Descriptor: | 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|